Tag: Kevin Barron

  • Kevin Barron – 2016 Parliamentary Question to the Department of Health

    Kevin Barron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kevin Barron on 2016-07-06.

    To ask the Secretary of State for Health, what assessment he has made of the (a) extent of the implementation of the Making Every Contact Count initiative by clinical commissioning groups and local authorities and (b) adequacy of training provided to staff to equip them to provide consistent self-care messages during consultations; and if he will make a statement.

    Alistair Burt

    Public Health England, Health Education England (HEE) and NHS England are collaborating with local authorities and National Health Service partners to support local uptake of the Making Every Contact Count (MECC) approach building on the many examples of implementation such as from Warwickshire, Medway and Wigan. Activities to support the commissioning, development and delivery of effective local training have been undertaken.

    To support MECC uptake by clinical commissioning groups (CCGs) and local authorities a provider requirement now exists within the NHS Standard Contract; and NHS England’s person-centred care Commissioning for Quality and Innovation for CCGs includes workforce skills that support the local MECC offer. The national MECC advisory group is linking with HEE’s national workforce programme and NHS England’s New Models of Care and Self-Care teams to support and equip the workforce with person centred skills to support and enable self-care and behaviour change. HEE has regional events to support MECC implementation activity across the Sustainable Transformation Plan footprints.

  • Kevin Barron – 2016 Parliamentary Question to the Department of Health

    Kevin Barron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kevin Barron on 2016-10-10.

    To ask the Secretary of State for Health, what assessment his Department has made of the potential effect of proposed reductions in the level of community pharmacy funding on the adequacy of provision of pharmaceutical advice and reassurance to members of the public.

    David Mowat

    The Government’s proposals for community pharmacy in 2016/17 and beyond, on which we have consulted, are being considered against the public sector equality duty, the family test and the relevant duties of my Rt. hon. Friend, the Secretary of State for Health, under the National Health Service Act 2006.

    Our assessments include consideration of the potential impacts on the adequate provision of NHS pharmaceutical services, including the supply of medicines, access to NHS pharmaceutical services, supplementary hours, non-commissioned services, individuals with protected characteristics, impacts on other NHS services, health inequalities, individuals with restricted mobility and access to healthcare for deprived communities.

    An impact assessment will be completed to inform final decisions and published in due course.

    Our proposals are about improving services for patients and the public and securing efficiencies and savings. We believe these efficiencies can be made within community pharmacy without compromising the quality of services or public access to them.

    Our aim is to ensure that those community pharmacies upon which people depend continue to thrive. We are consulting on the introduction of a Pharmacy Access Scheme, which will provide more NHS funds to certain pharmacies compared with others, considering factors such as location and the health needs of the local population.

    We want a clinically focussed community pharmacy service that is better integrated with primary care and public health in line with the Five Year Forward View. This will help relieve the pressure on general practitioners and accident and emergency departments, ensure better use of medicines and better patient outcomes, and contribute to delivering seven day health and care services.

    The Chief Pharmaceutical Officer for England, Dr Keith Ridge has commissioned an independent review of community pharmacy clinical services. The review is being led by Richard Murray, Director of Policy at The King’s Fund. The final recommendations will be considered as part of the development of clinical and cost effective patient care by pharmacists and their teams.

    NHS England is also setting up a Pharmacy Integration Fund to support the development of clinical pharmacy practice in a wider range of primary care settings, resulting in a more integrated and effective NHS primary care patient pathway.

    The rollout of the additional 1,500 clinical pharmacists announced by NHS England will help to ease current pressures in general practice by working with patients who have long term conditions and others with multiple medications. Having a pharmacist on site will mean that patients who receive care from their general practice will be able to benefit from the expertise in medicines that these pharmacists provide.

  • Kevin Barron – 2016 Parliamentary Question to the Department of Health

    Kevin Barron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kevin Barron on 2016-10-10.

    To ask the Secretary of State for Health, what assessment his Department has made of the potential effect of proposed reductions in the level of community pharmacy funding on the support available for frail and elderly people to live independently in their own homes.

    David Mowat

    The Government’s proposals for community pharmacy in 2016/17 and beyond, on which we have consulted, are being considered against the public sector equality duty, the family test and the relevant duties of my Rt. hon. Friend, the Secretary of State for Health, under the National Health Service Act 2006.

    Our assessments include consideration of the potential impacts on the adequate provision of NHS pharmaceutical services, including the supply of medicines, access to NHS pharmaceutical services, supplementary hours, non-commissioned services, individuals with protected characteristics, impacts on other NHS services, health inequalities, individuals with restricted mobility and access to healthcare for deprived communities.

    An impact assessment will be completed to inform final decisions and published in due course.

    Our proposals are about improving services for patients and the public and securing efficiencies and savings. We believe these efficiencies can be made within community pharmacy without compromising the quality of services or public access to them.

    Our aim is to ensure that those community pharmacies upon which people depend continue to thrive. We are consulting on the introduction of a Pharmacy Access Scheme, which will provide more NHS funds to certain pharmacies compared with others, considering factors such as location and the health needs of the local population.

    We want a clinically focussed community pharmacy service that is better integrated with primary care and public health in line with the Five Year Forward View. This will help relieve the pressure on general practitioners and accident and emergency departments, ensure better use of medicines and better patient outcomes, and contribute to delivering seven day health and care services.

    The Chief Pharmaceutical Officer for England, Dr Keith Ridge has commissioned an independent review of community pharmacy clinical services. The review is being led by Richard Murray, Director of Policy at The King’s Fund. The final recommendations will be considered as part of the development of clinical and cost effective patient care by pharmacists and their teams.

    NHS England is also setting up a Pharmacy Integration Fund to support the development of clinical pharmacy practice in a wider range of primary care settings, resulting in a more integrated and effective NHS primary care patient pathway.

    The rollout of the additional 1,500 clinical pharmacists announced by NHS England will help to ease current pressures in general practice by working with patients who have long term conditions and others with multiple medications. Having a pharmacist on site will mean that patients who receive care from their general practice will be able to benefit from the expertise in medicines that these pharmacists provide.

  • Kevin Barron – 2016 Parliamentary Question to the Department of Health

    Kevin Barron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kevin Barron on 2016-01-13.

    To ask the Secretary of State for Health, what steps he is taking to substitute the prescribing of high volume branded medicine with generic equivalents.

    George Freeman

    Generic substitution has happened in secondary care for many years, but is not currently permitted in primary care. The Department consulted on introducing primary care generic substitution in 2010, but did not progress the proposals following concerns about the potential impact on patient safety.

    Most general practitioner practices and clinical commissioning groups, formerly primary care trusts, have been pursuing and supporting policies of increasing generic prescribing for 15 years or more. Generic prescribing rates are already relatively high in England at 84.1% in 2014, as reported in the Health and Social Care Information Centre report: Prescriptions dispensed in the community: England 2004-14.

  • Kevin Barron – 2016 Parliamentary Question to the Department of Health

    Kevin Barron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kevin Barron on 2016-01-13.

    To ask the Secretary of State for Health, what estimate he has made of the potential annual savings to the NHS through greater generic substitution compared to using their reference originator products; and what assessment he has made of the obstacles to implementing such a policy for (a) inhalers and biologics and (b) after complex products.

    George Freeman

    The Government has made no such assessments. England has one of the highest levels of generic prescribing in Europe. In 2014, the Health & Social Care Information Centre report Prescriptions Dispensed in the community: England 2004-14, shows that of all medicines dispensed in 2014, 84.1% were dispensed generically.

    Prescribers are ultimately responsible for their own prescribing decisions. We expect them to always satisfy themselves that the medicines they consider appropriate for their patients can be safely prescribed and that patients are adequately monitored.

  • Kevin Barron – 2016 Parliamentary Question to the Department of Health

    Kevin Barron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kevin Barron on 2016-01-13.

    To ask the Secretary of State for Health, what discussions he has had with the Medicines and Healthcare Products Regulatory Agency about the requirement for some generic medicines to be given a brand name for clinical reasons; and what steps he is taking to ensure patients receive the brand name medicine specified.

    George Freeman

    The Medicines and Healthcare products Regulatory Agency (MHRA) is the Executive Agency of Department of Health with overall responsibility for medicines licensing.

    The responsibility for prescribing rests with the practitioner who has clinical responsibility for their patient’s care and we would expect practitioners to take any relevant guidance into account when making their prescribing decisions.Prescribers utilise a wide range of information to inform their prescribing decisions including decision support systems and authoritative guidance such as that from the MHRA, the National Institute for Health and Care Excellence and the British National Formulary.

    In primary care, if it is clinically appropriate for an individual patient to be maintained on a specific manufacturer’s product then the prescriber can specify this on the prescription for that product to be dispensed. Officials from the Department and MHRA liaise as required on the application of this policy.

  • Kevin Barron – 2016 Parliamentary Question to the Department of Health

    Kevin Barron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kevin Barron on 2016-01-13.

    To ask the Secretary of State for Health, what plans he has to include generic medicines which are required to have a brand name by the MHRA and are already subject to market competition alongside originator medicines in the Statutory Scheme of Control the Prices of Branded Health Service Medicines.

    George Freeman

    The Department consulted on options to amend the Statutory Scheme regulations which control the prices of branded health service medicines. Both the voluntary Pharmaceutical Price Regulation Scheme and the statutory scheme include all health service medicines with a brand name, including those required by the Medicines and Healthcare products Regulatory Agency to have a brand name. The Department did not propose any changes to the scope of the statutory scheme in this respect and has not made an estimate of the cost of removing those branded medicines from the statutory scheme.

    The Department received responses from a range of organisations including National Health Service, independent bodies and pharmaceutical industry. The Department is currently analysing the responses from a range of organisations including NHS, independent bodies and pharmaceutical industry.

    The consultation and impact assessment can be accessed using the following link.

    https://www.gov.uk/government/consultations/pricing-of-branded-health-service-medicines

  • Kevin Barron – 2016 Parliamentary Question to the Department of Health

    Kevin Barron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kevin Barron on 2016-01-13.

    To ask the Secretary of State for Health, what estimate he has made of the cost to the NHS of removing generic medicines required to have a brand name by the MHRA from the Statutory Scheme of Control the Prices of Branded Health Service Medicines.

    George Freeman

    The Department consulted on options to amend the Statutory Scheme regulations which control the prices of branded health service medicines. Both the voluntary Pharmaceutical Price Regulation Scheme and the statutory scheme include all health service medicines with a brand name, including those required by the Medicines and Healthcare products Regulatory Agency to have a brand name. The Department did not propose any changes to the scope of the statutory scheme in this respect and has not made an estimate of the cost of removing those branded medicines from the statutory scheme.

    The Department received responses from a range of organisations including National Health Service, independent bodies and pharmaceutical industry. The Department is currently analysing the responses from a range of organisations including NHS, independent bodies and pharmaceutical industry.

    The consultation and impact assessment can be accessed using the following link.

    https://www.gov.uk/government/consultations/pricing-of-branded-health-service-medicines

  • Kevin Barron – 2015 Parliamentary Question to the Department of Health

    Kevin Barron – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kevin Barron on 2015-09-17.

    To ask the Secretary of State for Health, what assessment he has made of the role of community pharmacies in keeping people healthy.

    Alistair Burt

    We have long recognised that community pharmacy teams play a vital role in improving people’s health, preventing ill-health and helping to reduce health inequalities. Informed by a growing evidence base, we have enabled community pharmacy to deliver a wide range of public health services. We have actively supported the implementation of Healthy Living Pharmacies, with qualified health champions on site reaching out to, and improving the health of, people in their communities.

    Public Health England (PHE) keeps under review the progress that pharmacy is making on keeping people healthy and is providing system leadership for pharmacy’s public health role and strategic leadership for the acceleration and spread of Healthy Living Pharmacies across the country. PHE’s vision for pharmacy is one in which community pharmacy teams are fully integrated into the local primary care networks, playing an appropriate and pivotal role in improving the health of people in England. PHE has built a strong relationship with the sector, seeking to utilise its unique offering of access, location and an informal environment, with trusted staff that reflect the background of the communities that they serve. PHE is embedding pharmacy in its priority public health programmes such as prevention, early detection and management of blood pressure, NHS Health Checks and smoking cessation.

  • Kevin Barron – 2019 Valediction Speech

    Below is the text of the speech made by Kevin Barron, the Labour MP for Rother Valley, in the House of Commons on 5 November 2019.

    I rise to make my final contribution after more than 36 years in this House. As I said when I announced that I was standing down, it has been the honour of my life to represent Rother Valley, a constituency that I first moved to at the age of eight, when my father, a Durham miner, moved to the south Yorkshire coalfields.

    Having been elected in 1983, my baptism came very shortly after, when 4,500 miners went on strike for 12 months. With the Orgreave coke works in my constituency, I was kept on my toes. That was followed by three years as the Parliamentary Private Secretary to the then Leader of the Opposition. I learnt quite a lot of things that I will not be sharing this afternoon—I am not even tempted to talk about the Whips Office, as the right hon. Member for Derbyshire Dales (Sir Patrick McLoughlin) has just done.

    The major work that I have done in the House is with Select Committees. When I was first elected, I served on the Energy Committee, and then for a short time, I was a member of the Environment Committee. I chaired the Health Committee for five years, from 2005 to 2010. One of the earliest things that Committee did was to secure a free vote in the House on bringing in a comprehensive ban on smoking in public places. Some people said at the time that it would be the end of the world as we knew it, but now people say that it is the most popular piece of public health legislation that the House has ever introduced. I spent eight years chairing the Committee on Standards, until September last year. We did not have quite as great a result as we did with the smoking ban, but my intention all along was to ensure that this place was better thought of by the people outside who elect and send us here. I think that to some extent we were moving along quite nicely on that, until something happened in 2016 that seems to have knocked us back quite a bit. Select Committee work is something that I have enjoyed.

    With regard to local achievements, clearly there are many, but the main achievement that I and my staff have had over many years is dealing with individual casework, for the people who come along and need help, perhaps because they have been unable to communicate their concerns. I have always said that I have been a voice for the voiceless in Rother Valley, speaking up on their behalf. Another thing I have been involved with in the constituency is coalfield regeneration. The advanced manufacturing park is now in the Rotherham constituency, but it used to be in Rother Valley when it was first put in by a Labour Government. It shows that we are recognised as having some of the finest manufacturing anywhere in the world. That came out of the old Orgreave coke works and the coalmine site. Such developments have transformed parts of south Yorkshire, and my voice and that of the Government were there for that on many occasions.​
    Finally, I want to say a few words of thanks to some individuals. For the last eight general elections, my friend and colleague Alan Goy has been my political agent. All Members will know how important it is to have a good relationship with their political agent. I also want to thank the staff who have supported me during my tenure. I will thank, in particular, my current staff, Sheena Woolley, Jacquie Falvey and Natalie Robinson, who support me in the constituency, and Kate Edwards and Michael Denoual, who work here in Parliament.

    As the right hon. Member for Derbyshire Dales said, your wife is a massive support in this job. Sadly, I lost my first wife Carol in 2008, but Andree, who I married a few years ago, has been a pillar of support. It would be difficult for anybody to do this job without that type of support at home.

    I do not want to turn this into a full-scale Oscars speech, so I will end by thanking the people of Rother Valley, who I have been honoured to represent. Whoever wins the seat at the election, I hope that they will feel the same satisfaction representing it that I have felt for many years.